CHANGE MY LOCATION
Business News
McCain tells convention, nation he'll bring change- John McCain, a POW turned political rebel, vowed Thursday night to vanquish the "constant partisan rancor" that grips Washington as he launched his fall campaign for the White House. "Change is coming," he promised the roaring Republican National Convention and a prime-time television audience.
- President Bush's top defense advisers have recommended he maintain 15 combat brigades in Iraq until the end of the year contrary to expectations that the improved security in Iraq would allow for quicker cuts, The Associated Press has learned.
Rescuers can't get aid to starving Haitian city- The convoy rumbled out of the U.N. base toward a flooded, starving and seething city Thursday, carrying some of the first food aid since Tropical Storm Hanna killed 137 Haitians and drowned Gonaives in muddy water three days ago.
Obama says GOP avoiding issues on voters' minds- Democratic presidential candidate Barack Obama said Thursday that Republicans at their national convention are attacking him to avoid talking about the sagging economy and housing problems.
- Soldier suicides this year could surpass the record rate of last year, Army officials said Thursday, urging military leaders at all levels to redouble prevention efforts for a force strained by two wars.
David Spade is the father of Playboy pinup's baby- David Spade is the father of Playboy playmate Jillian Grace's newborn daughter, Spade's representative said Thursday. The baby girl was born Aug. 26 in Missouri, and Spade plans to visit her on his first break from filming the CBS sitcom "Rules of Engagement," publicist Meredith O'Sullivan said.
Giants kick off Super Bowl defense with win- The New York Giants won the Super Bowl with defense and they kicked off defense of that title with more of the same.
Djokovic beats Roddick at Open; Federer advances- Novak Djokovic heard what Andy Roddick said about him and didn't like it one bit.
BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
SAN FRANCISCO
(Map)
-
Researchers presented the data at the American Association for Cancer
Research-National Cancer Institute-European Organization for Research and
Treatment of Cancer International Conference on Molecular Targets and Cancer
Therapeutics in
"These results demonstrate the potential of BSI-401 to treat one of the
most deadly and difficult-to-treat cancers," said James L. Abbruzzese,
professor of gastrointestinal medical oncology and associate medical director
of the gastrointestinal center at the University of Texas M.D.
Pancreatic cancer kills more than 30,000 each year in the
In animals with orthotopic human pancreatic tumors, BSI-401 administered significantly reduced tumor burden and extended survival. In addition, a synergistic effect was seen with BSI-401 in combination with oxaliplatin.
PARP is a well-characterized and validated target for cancer therapies. PARP-1 plays a central role in cell proliferation in DNA repair, and the PARP-1 gene is upregulated in certain tumor types.
BiPar's novel, proprietary PARP inhibitors are the first of a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical and early clinical studies suggest the drugs selectively induce tumor cell death and are active against a broad range of tumor types.
BiPar's lead PARP inhibitor, BSI-201, is set to enter a series of Phase1b and Phase 2 trials in major cancers by the end of this year.
About BiPar Sciences
BiPar Sciences Inc. (http://www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a pipeline of novel, tumor-selective drugs designed to meet the significant unmet needs of cancer patients.
|
|
